Handelsavisen
prelaunch
Companies Healthcare 263050.KQ
26
263050.KQ KOSDAQ Pharmaceuticals

263050.Kq

$959,00
Open in Charts → Attach watcher ⌖
KRW
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
35,3B KRW
P/E
EV / Rev
Div yield
Op margin
-249,0 %
ROE
-156,6 %
Net margin
-232,4 %
Debt / equity
1,02
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the pharmaceuticals industry, focusing on drug development and medical research, and generates revenue primarily through the sale of pharmaceutical products and related services.

Business. The company operates in the pharmaceuticals industry, focusing on drug development and medical research, and generates revenue primarily through the sale of pharmaceutical products and related services.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-156,6 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 263050.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 263050.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the pharmaceuticals industry, focusing on drug development and medical research, and generates revenue primarily through the sale of pharmaceutical products and related services.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a debt-to-equity ratio of 1.02, indicating a relatively balanced mix of debt and equity financing. However, the company's liquidity position is weak, with a current ratio of 0.44, suggesting that it may struggle to meet short-term obligations. The company's price-to-book ratio is 2.31, and its price-to-tangible-book ratio is also 2.31, indicating that the market is valuing the company's intangible assets at a premium. The company's enterprise value to revenue ratio is 4.51, which is relatively high, suggesting that the market is paying a premium for each dollar of revenue.

    The company's profitability is negative, with a return on equity of -1.566 and a return on assets of -0.5807, indicating that it is not generating returns for its shareholders or effectively utilizing its assets. The company's operating income is negative at -25,630,896,360, and its net income is also negative at -23,923,569,790, reflecting significant financial distress. These metrics are far below the industry median for profitability, indicating that the company is underperforming relative to its peers.

    The company's revenue is concentrated in a single geographic region, as disclosed in its financial statements, with no specific breakdown provided. The company does not disclose segment-level revenue, making it difficult to assess the contribution of different business lines to overall performance. The lack of segment data limits the ability to evaluate the company's diversification and exposure to different markets.

    The company's growth trajectory is negative, with a significant decline in revenue and profitability. The company's operating cash flow is negative at -14,059,760,650, and its free cash flow is also negative at -23,078,155,140, indicating that it is not generating sufficient cash to fund operations or invest in growth. The company's capital expenditure is negative at -647,966,520, suggesting that it is not investing in new projects or expanding its operations. The company's outlook for the current fiscal year is negative, with no indication of improvement in the near term.

    The company faces significant financial risks, including a high debt-to-equity ratio and a weak liquidity position. The company's net cash is negative after subtracting total debt, indicating that it may need to raise additional capital or refinance its debt to remain solvent. The company's dilution potential is low, as there is no indication of share issuance or other dilutive events. However, the company's financial distress may lead to the need for equity financing in the future, which could result in dilution for existing shareholders.

    The company has not disclosed any recent events, such as filings or transcripts, that would provide insight into its current financial condition or strategic direction. The lack of recent disclosures limits the ability to assess the company's response to market conditions and its plans for addressing its financial challenges. The company's financial statements do not provide detailed information on recent developments, making it difficult to evaluate its prospects for recovery.

    Key takeaways
    • The company is experiencing significant financial distress, with negative operating and net income.
    • The company's liquidity position is weak, with a current ratio of 0.44.
    • The company's profitability is far below industry medians, indicating underperformance.
    • The company is not generating positive cash flows, with both operating and free cash flows being negative.
    • The company's capital structure is balanced, but its financial distress may require additional financing.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $959,00
    Market cap
    $35.32B
    Enterprise value
    $46.43B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    2.3x
    P / Tangible book
    2.3x
    Tangible book
    $15.28B
    Net cash
    -$11.11B
    Current ratio
    0.4
    Debt / equity
    1.0
    ROA
    -58.1%
    ROE
    -1.6%
    Cash conversion
    59.0%
    CapEx / revenue
    -6.3%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-249,0 %Bottom quartile
    Net Margin-232,4 %Bottom quartile
    ROE-156,6 %Bottom quartile
    Capex / Rev-6,3 %Below median
    D/E1,02Bottom quartile
    Cash Conv0,59Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • 263050.KQ Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    263050.KQCanonical
    KOSDAQ · KRW

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage